Europe Viscosupplementation Market Size
Europe Viscosupplementation Market Analysis
The Europe Viscosupplementation Market size is estimated at USD 1.27 billion in 2025, and is expected to reach USD 1.74 billion by 2030, at a CAGR of 6.5% during the forecast period (2025-2030).
The viscosupplementation market in Europe is experiencing significant growth, primarily driven by the increasing prevalence of osteoarthritis and the introduction of advanced and combination products. Joint injuries resulting from road accidents, such as dislocations, ligament tears, and cartilage damage, often lead to severe orthopedic conditions. According to data from Versus Arthritis published in May 2023, over 10 million individuals in the United Kingdom suffer from arthritis annually, equating to one in six people facing pain, fatigue, and mobility challenges. This high incidence of joint-related conditions underscores the growing demand for effective treatment solutions, thereby creating opportunities for market expansion. Consequently, the rising burden of orthopedic diseases linked to accidents is expected to significantly contribute to the growth of the viscosupplementation market in the region.
Osteoarthritis (OA), a condition predominantly affecting older adults, is becoming increasingly common due to Europe's aging population. This demographic shift is driving the need for effective treatments to manage joint pain and improve mobility. The World Economic Forum, in its September 2023 report, projected that the old-age dependency ratio in Europe would rise from 36% in 2023 to approximately 59% by 2070. Additionally, the European Commission's November 2023 report forecasted that by 2100, over 30% of the EU's population would be aged 65 or older, with nearly half a million centenarians by 2050. Modern lifestyle factors, including sedentary habits and obesity, further exacerbate joint stress and OA prevalence. This growing demand for viscosupplementation treatments highlights the market's potential for sustained growth. As a result, the aging population and lifestyle-related factors are expected to remain key drivers of market expansion.
Strategic initiatives by market players, such as product launches, partnerships, mergers, acquisitions, and collaborations, are further enhancing the availability of innovative products and strengthening competitive positioning. For instance, in May 2023, BioSenic Paris reacquired global IP rights and announced updates on the development of JTA-004, an injectable viscosupplement designed to address a specific subtype of knee osteoarthritis with combined anti-pain and anti-inflammatory properties. Such developments underscore the industry's commitment to innovation and its focus on addressing unmet medical needs. Consequently, these strategic activities are anticipated to play a pivotal role in driving the market's growth by fostering innovation and expanding product offerings.
In conclusion, the viscosupplementation market in Europe is poised for growth, driven by the increasing prevalence of osteoarthritis, an aging population, and strategic initiatives by market players. However, challenges such as regulatory barriers and limited awareness of viscosupplementation treatments may pose obstacles to market expansion.
Europe Viscosupplementation Market Trends
The Single Injection Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Viscosupplementation involves injecting hyaluronic acid (HA) into affected joints, intending to restore the physiologic viscoelasticity in the synovial fluid (SF) without inflammation. The single injection segment is poised for substantial growth, driven by factors like enhanced convenience for both physicians and patients, a surge in demand for outpatient surgeries emphasizing same-day care (encompassing both preventive and diagnostic procedures), and a heightened emphasis from companies on developing single injections, specifically for osteoarthritis treatment.
The single injection therapy matches the effectiveness of traditional dosage regimes while being more economical. By consolidating treatments into one injection, it minimizes hospital visits and procedures, thereby reducing associated risks, including potential side effects. Moreover, the growing number of research activities on single injection is expected to lead to the launch of more products, thereby boosting market growth. For instance, the study published in Elsevier Journal in January 2023 evaluated a single intra-articular injection of non-crosslinked KiOmedineCM-Chitosan in the Netherlands and reported it is safe and effective for treating symptomatic knee osteoarthritis and pain reduction with a high response rate. Thus, the significant safety and efficacy of single injections are expected to increase their demand and contribute to segmental growth.
Further, according to the study published in Open Acess Rhemautology in September 2024, A single injection of hyaluronic acid (HA) into the hip joint significantly alleviated pain for osteoarthritis patients, with benefits noted at various follow-ups. Post-injection, patients reported better joint function, underscoring the treatment's positive influence on daily activities. The procedure was largely well-received, with no major adverse events. Any mild side effects that did occur were both rare and easily managed. These results underscore the promise of single-injection viscosupplementation as a safe and effective treatment for hip osteoarthritis, bolstering its rising adoption in clinical settings and fueling segment growth.
Hence, several benefits are associated with single injections in the management of osteoarthritis, and increasing adoption of single injections is expected to boost the segment’s growth over the forecast period.
Germany is Expected to Hold a Significant Market Share Over the Forecast Period
The viscosupplementation market is expected to grow in Germany owing to the rising burden of road and sports injuries, the growing aging population, and the increasing launches of innovative products.
Injuries sustained from road accidents can affect joints, resulting in dislocations, ligament tears, and cartilage damage. Serious joint injuries may require surgical repair or reconstruction using orthopedic devices, which contributes to the growth of the market. For instance, according to the 2023 published statistics by the Federal Statistics Office in February 2023, roughly 21,600 people were injured in road traffic accidents in Germany. The number increased by approximately 900, or 5%, compared to the same month of the previous year. Thus, the increasing number of accidental injuries is expected to increase the burden of orthopedic disease and boost the market’s growth in the country.
In addition, the increasing geriatric population, which is susceptible to orthopedic diseases, is likely to boost market growth over the forecast period. For instance, according to the 2023 statistics published by the UN Population Fund, in Germany, a large proportion of the population was estimated to be aged 15-64, accounting for 63.6%. In addition, as per the Federal Statistical Office 2024, by mid-2035, Germany's population aged 67 and over is projected to increase by approximately 4 million, reaching a total of at least 20 million by 2070. Thus, the expected increase in the geriatric population will increase the demand for viscosupplementation products, thereby boosting market growth.
Thus, the rising burden of orthopedic injuries and the growing geriatric population are expected to increase the market’s growth in Germany over the forecast period.
Europe Viscosupplementation Industry Overview
Europe’s viscosupplementation market is semi-consolidated, with major players adopting various business strategies such as partnerships, product launches, approvals, and collaboration to maintain their market position. Some of the key market players include Anika Therapeutics Inc., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici SpA, Sanofi SA, Johnson & Johnson Services Inc., and Zimmer Biomet.
Europe Viscosupplementation Market Leaders
-
Ferring Pharmaceuticals
-
Fidia Farmaceutici s.p.a.
-
Zimmer Biomet Holdings
-
OrthogenRx Inc.
-
Sanofi SA
- *Disclaimer: Major Players sorted in no particular order
Europe Viscosupplementation Market News
- February 2024: IBSA UK introduced SINOVIAL, an advanced formulation targeting musculoskeletal conditions, leveraging its proprietary technology.
- March 2023: BioSenic revealed a re-evaluation of the results from its Phase III trial for JTA-004, an enhanced viscosupplement aimed at treating knee osteoarthritis (OA).
Europe Viscosupplementation Industry Segmentation
Viscosupplements are injections of hyaluronic acid for diarthrodial joints, intending to restore the rheological properties of the synovial fluid, thereby producing analgesia, mechanical, chondroprotective, and anti-inflammatory effects. Viscosupplements are usually preferred by healthcare providers to treat osteoarthritis. They may also benefit patients with certain other kinds of arthritis, such as rheumatoid arthritis.
Europe's viscosupplementation market is segmented by dosage, end user, and geography. By dosage, the market is segmented into single injections, three injections, and five injections. By end user, the market is segmented into hospitals, ambulatory surgical centers, and others. Other end users include specialty clinics, and rehabilitation centers, among others. By geography, the market is segmented into Germany, the United Kingdom, France, Italy, Spain, and Rest of Europe. The report offers the value (USD) for all the above segments.
By Dosage | Single Injection |
Three Injections | |
Five Injections | |
By End User | Hospitals |
Ambulatory Surgical Centers | |
Others (Specialty Clinics, and Rehabilitation Centers, Among Others) | |
Geography | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe |
Single Injection |
Three Injections |
Five Injections |
Hospitals |
Ambulatory Surgical Centers |
Others (Specialty Clinics, and Rehabilitation Centers, Among Others) |
Germany |
United Kingdom |
France |
Italy |
Spain |
Rest of Europe |
Europe Viscosupplementation Market Research FAQs
How big is the Europe Viscosupplementation Market?
The Europe Viscosupplementation Market size is expected to reach USD 1.27 billion in 2025 and grow at a CAGR of 6.5% to reach USD 1.74 billion by 2030.
What is the current Europe Viscosupplementation Market size?
In 2025, the Europe Viscosupplementation Market size is expected to reach USD 1.27 billion.
Who are the key players in Europe Viscosupplementation Market?
Ferring Pharmaceuticals, Fidia Farmaceutici s.p.a., Zimmer Biomet Holdings, OrthogenRx Inc. and Sanofi SA are the major companies operating in the Europe Viscosupplementation Market.
What years does this Europe Viscosupplementation Market cover, and what was the market size in 2024?
In 2024, the Europe Viscosupplementation Market size was estimated at USD 1.19 billion. The report covers the Europe Viscosupplementation Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Viscosupplementation Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on: December 20, 2024
Europe Viscosupplementation Industry Report
Statistics for the 2025 Europe Viscosupplementation market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Viscosupplementation analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.